Search with one or more keywords

This page gives you access to all the studies carried out by French researchers, identified on Covid-19.

To view other resources related to Covid-19, click here.

xml
XML

Export to XML

Please choose the format :

XML
XML-DDI
pdf
PDF

Export to PDF

Which version do you want to export ?

Download full content
Download light content
csv
CSV (Excel)

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection
Export to CSV

Covid-19 : 84 forms

Sorting of results :

COVIDET - Evaluation of SARS-CoV-2 seroprevalence among prison inmates

Head : Mellon Guillaume

Version 1
Voir
View
Overview

13

Last update : 05/05/2021

COVIDET - Evaluation of SARS-CoV-2 seroprevalence among prison inmates

Head : Mellon Guillaume

Main objective

Evaluate the prevalence of SARS-CoV-2 infection among prison inmates in detention institutions in the Ile-de-France region, by measuring SARS-CoV-2 antibody levels in plasma

Inclusion criteria

Subjects fulfilling all of the following criteria will be included in the study:
o Female inmates on the lists provided by the detention institutions or male inmates randomly selected from the lists provided by the detention institutions.
o Aged 18 to 80 years.
o Freely given, informed consent form signed.

Last update : 05/05/2021

Voir
View

COVIDIV - Collateral damage of the COVID-19 pandemic observed among patients receiving treatment with intravitreal (IVT) injections of antiangiogenic agents

Head : Mauget-Faÿsse Martine

Version 1
Voir
View
Overview

14

Last update : 04/21/2021

COVIDIV - Collateral damage of the COVID-19 pandemic observed among patients receiving treatment with intravitreal (IVT) injections of antiangiogenic agents

Head : Mauget-Faÿsse Martine

Main objective

Describe the changes in visual acuity among patients receiving treatment with repeat IVT injections of antiangiogenic agents during the COVID-19 epidemic, between September 2019 and May 2021

Inclusion criteria

Patient aged 18 years and over
-Eye disorder requiring treatment with repeat IVT injections of antiangiogenic agents: Exudative ARMD, macular oedema associated with diabetes or secondary to retinal vein occlusion.
-Initiation of treatment with repeat IVT injections before 01/10/2019

Last update : 04/21/2021

Voir
View

COVIDonneur - SARS-CoV-2 seroprevalence study in the blood donor population

Head : Gallian Pierre, Emerging Viruses Units, 20-21 Boulevard Jean Moulin, 13005 Marseille

Version 1
Voir
View
Overview

15

Last update : 05/06/2021

COVIDonneur - SARS-CoV-2 seroprevalence study in the blood donor population

Head : Gallian Pierre, Emerging Viruses Units, 20-21 Boulevard Jean Moulin, 13005 Marseille

Main objective

Estimate the seroprevalence of SARS-CoV-2 infection in the French blood donor population (18-70 years) in different geographical zones (mainland France and overseas departments), at different times in the epidemic, so as to model the progression of the epidemic

Inclusion criteria

Accepted blood donors
aged 18 to 70 years.
in the geographical zones of interest
having agreed to the use of their samples for research

Plasma samples > 500 µL in volume

Last update : 05/06/2021

Voir
View

COVID-PRO-IMPACT - impact of the COVID-19 pandemic on the psychological quality of life of healthcare professionals

Head : CHENE Gautier, Hôpital Femme Mère Enfant

Version 1
Voir
View
Overview

16

Last update : 04/06/2021

COVID-PRO-IMPACT - impact of the COVID-19 pandemic on the psychological quality of life of healthcare professionals

Head : CHENE Gautier, Hôpital Femme Mère Enfant

Main objective

Study the evolution of the psychological quality of life of healthcare professionals during the confinement period linked to the COVID-19 pandemic

Inclusion criteria

person over 18
person exercising a profession in the field of health
person who expressed his non-opposition

Last update : 04/06/2021

Voir
View

COVIGENET - Cohort of patients with Covid-19: creation of a biological sample collection with clinical characterisation

Head : MAITRE Bernard

Version 1
Voir
View
Overview

17

Last update : 05/05/2021

COVIGENET - Cohort of patients with Covid-19: creation of a biological sample collection with clinical characterisation

Head : MAITRE Bernard

Main objective

Investigation for a phenotype/genotype correlation modulating the severity of Covid-19 disease

Inclusion criteria

Proven diagnosis of COVID-19 (based on RT-PCR or chest CT-scan)
Patients of all ages
Registered with the general social security scheme
Consent form signed by the patient or by the legal representatives for minors

Last update : 05/05/2021

Voir
View

COVIMMUNE 2 - Study of the incidence of SARS-CoV-2 infection in the Alpes-Maritimes administrative department based on the analysis of specific humoral and cellular response while easing lockdown restrictions

Head : SEITZ-POLSKI Barbara, laboratoire d'Immunologie hôpital Archet 1

Version 1
Voir
View
Overview

18

Last update : 06/09/2021

COVIMMUNE 2 - Study of the incidence of SARS-CoV-2 infection in the Alpes-Maritimes administrative department based on the analysis of specific humoral and cellular response while easing lockdown restrictions

Head : SEITZ-POLSKI Barbara, laboratoire d'Immunologie hôpital Archet 1

Main objective

Determine the incidence of SARS-CoV-2 infection, over an 18-month period after the end of the first lockdown in a group of subjects whose professions involve contact with the general public.
Determine the risk of re-infection after initial infection with SARS-CoV-2 confirmed by a positive serology test.

Inclusion criteria

Any healthy adult volunteers, exposed to the general public from 11 May 2020, informed of the study via partner institutions (06 Administrative Department Council), registered with a social security scheme.

Last update : 06/09/2021

Voir
View

Please wait...

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

View Edit Create here